Sort
130,381 grants matching “hiv”
Mid Southern Primary Care Networks Node
$814,688Li-Tzy T Wu · Duke University · UG1 · FY2016 · DA
TOPICAL PROTEGRINS TO PREVENT STDS &HIV INFECTION
$814,680University Of California Los Angeles · P01 · FY2003 · AI
Antibody Responses in Aging SIV Infected Monkeys
$814,638Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2016 · AI
Optical Chip Test for T Cell Function in HIV Patients
$814,595Ngimat Company · R44 · FY2005 · AI
Tulane/LSU Pediatric AIDS Clinical Trials Unit
$814,570Tulane University Of Louisiana · U01 · FY2003 · AI
Targeting the HIV/SIV reservoir at time of ART initiation
$814,441Afamefuna Okoye · Oregon Health & Science University · R01 · FY2022 · AI
Core G: Clinical Cohort and Comorbidity Research
$814,404Mari M Kitahata · University Of Washington · P30 · FY2019 · AI
Evaluating the role of opioid medication assisted therapies in HIV-1 Persistence for persons living with HIV and opioid use disorders
$814,393Sandra Ann Springer · Yale University · R33 · FY2022 · DA
Developing Durable, Env-Boosted CAR T Cells for HIV Cure
$814,373Christopher W Peterson · Fred Hutchinson Cancer Center · R01 · FY2025 · AI
Hodgkin Lymphoma in PLWH in South Africa: TB, EBV, and Tumor Molecular Markers
$814,364Richard F. Ambinder · Johns Hopkins University · R01 · FY2022 · CA
Use of ARV Drug Levels in DBS to Assess and Manage ART Adherence in South Africa
$814,293Robert H Remien · New York State Psychiatric Institute Dba Research Foundation For Mental Hygiene, Inc · R01 · FY2016 · AI
Pharmacogenomics of HIV Therapy
$814,283David W Haas · Vanderbilt University Medical Center · R01 · FY2022 · AI
California Hub for HIV/STI/SUD Prevention Research with Reentry Populations
$814,282Nina Thawata Harawa · University Of California Los Angeles · R61 · FY2024 · DA
Vascular contributions to HIV-associated Neurocognitive Disorders (HAND)
$814,209Jose Gutierrez · Columbia University Health Sciences · R01 · FY2023 · AG
Expertise in Using Bitter Taste Receptor Blockers to Improve the Palatability of Pediatric Medicines: Trained Human Sensory Panels
$814,149Peter Silvera · Advanced Bioscience Laboratories, Inc. · N01 · FY2025 · AI
Expansion of SARS-CoV-2 Testing Supplement, Chicago Clinical Trials Unit
$814,136Babafemi O Taiwo · Northwestern University At Chicago · UM1 · FY2020 · AI
Immunophenotyping for precision medicine for cardiovascular disease in people living with HIV
$814,084Robert C Kaplan · Albert Einstein College Of Medicine · R01 · FY2021 · HL
Family Planning Promotion in HIV Infected Zambians
$814,080University Of Alabama At Birmingham · R01 · FY2002 · HD
Protection against early SIV brain injury with adjunctive therapy to cART
$814,050Dennis Larry Kolson · University Of Pennsylvania · R01 · FY2023 · NS
HPV & Cervix Neoplasia in a Large, Long Term HIV + Cohort
$814,047Howard D Strickler · Albert Einstein College Of Medicine · R01 · FY2012 · CA
Infant Immunoprophylaxis against a Primate Lentivirus
$814,028Ruth Margrit Ruprecht · Dana-Farber Cancer Inst · R37 · FY2010 · AI
Blocking type I interferon signaling to reverse T cell exhaustion and control HIV-1 reservoirs
$814,022Lishan Su · University Of Maryland Baltimore · R01 · FY2022 · AI
Targeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIV
$813,950Rachel Lena Rutishauser · University Of California, San Francisco · R01 · FY2023 · AI
Transmission of HIV-Associated XDR TB in Rural South Africa
$813,935Nippie Sarita Shah · Albert Einstein College Of Medicine · R01 · FY2010 · AI
Short-course rifapentine for TB prevention for all: clinical pharmacology matters
$813,899Kelly E. Dooley · Vanderbilt University Medical Center · R37 · FY2025 · AI